REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFondation Ophtalmologique Adolphe de Rothschild

About this trial

The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.

Eligibility criteria

Qualifiers

Age 18 or older

Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and/or MCA) proved on CTA or MRA.

Symptoms onset < 24h at imaging

Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more.

Disqualifiers

Contraindication to MT

Patient over 80 years old with >10 microbleeds on pre-treatment MRI

Pre-existing dependency with mRS ≥3.

Known tandem ICA-MCA occlusions requiring stenting

Trial design

Treatments tested in this trial

  • Cangrelor
  • best medical management

Treatment groups

368 Participants
are divided into 2 treatment groups

Sponsors and collaborators